人胚胎干細(xì)胞H9，曾用名WA09。每支細(xì)胞可復(fù)蘇至一個(gè)T25，3至4天后會(huì)形成30至40個(gè)克隆。將H9（SCSP-302）細(xì)胞使用mTeSR1（STEM CELL）培養(yǎng)液馴化后得到，培養(yǎng)時(shí)無需飼養(yǎng)層。
組織來源：人胚胎內(nèi)細(xì)胞團(tuán)

形態(tài)：球形克隆，貼壁生長(zhǎng)

培養(yǎng)基配方：

使用 hES/hiPS無血清培養(yǎng)液套裝（SCSP-662）培養(yǎng)、傳代、凍存。

備注:

完全培養(yǎng)液： mTeSR1 人ES/iPS細(xì)胞無飼養(yǎng)層完全培養(yǎng)試劑盒 （85850）

傳代消化液：溫和分離細(xì)胞試劑 （07174）

凍存液：無血清無動(dòng)物成分細(xì)胞凍存液 （ 07930）

基質(zhì)膠：hES 專用基質(zhì)膠 （BD，354277）

氣相：空氣，95%；二氧化碳，5%。 溫度：37℃。

完全凍存液：免程序降溫細(xì)胞凍存液（低血清）(SD0001)

聲明：產(chǎn)品僅科研使用。

PubMed=2567177; DOI=10.1089/aid.1989.5.253

Mann D.L., O'Brien S.J., Gilbert D.A., Reid Y.A., Popovic M., Read-Connole E., Gallo R.C., Gazdar A.F.

Origin of the HIV-susceptible human CD4+ cell line H9.

AIDS Res. Hum. Retroviruses 5:253-255(1989)

PubMed=2193399; DOI=10.1126/science.2193399

Rubinstein E.

The untold story of HUT78.

Science 248:1499-1507(1990)

PubMed=1460674; DOI=10.1093/jnci/84.24.1922

Chen T.-R.

Karyotypic derivation of H9 cell line expressing human immunodeficiency virus susceptibility.

J. Natl. Cancer Inst. 84:1922-1926(1992)

PubMed=8320746; DOI=10.1093/jnci/85.14.1168

Bunn P.A. Jr., Whang-Peng J., Gazdar A.F., Minna J.D., Carney D.N.

Karyotypic derivation of H9 cell line.

J. Natl. Cancer Inst. 85:1168-1169(1993)

PubMed=8127147

Heyman M., Grander D., Brondum-Nielsen K., Cederblad B., Liu Y., Xu B., Einhorn S.

Interferon system defects in malignant T-cells.

Leukemia 8:425-434(1994)

PubMed=8641406; DOI=10.1111/j.1600-0609.1996.tb00721.x

Borgonovo Brandter L., Heyman M., Rasool O., Liu Y., Grander D., Einhorn S.

p16INK4/p15INK4B gene inactivation is a frequent event in malignant T-cell lines.

Eur. J. Haematol. 56:313-318(1996)

PubMed=17170727; DOI=10.1038/sj.leu.2404486

Sandberg Y., Verhaaf B., van Gastel-Mol E.J., Wolvers-Tettero I.L.M., de Vos J., Macleod R.A.F., Noordzij J.G., Dik W.A., van Dongen J.J.M., Langerak A.W.

Human T-cell lines with well-defined T-cell receptor gene rearrangements as controls for the BIOMED-2 multiplex polymerase chain reaction tubes.

Leukemia 21:230-237(2007)

PubMed=20164919; DOI=10.1038/nature08768

Bignell G.R., Greenman C.D., Davies H., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F., Campbell P.J., Futreal P.A., Stratton M.R.

Signatures of mutation and selection in the cancer genome.

Nature 463:893-898(2010)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017

Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

A landscape of pharmacogenomic interactions in cancer.

Cell 166:740-754(2016)